mhra

Stable4 articles4 sourcesDernière mise à jour: hier

Sujets associéssemaglutide Wegovy GLP-1 receptor agonist weight loss obesity 영국 의약품규제청 진통제 항생제

Derniers articles

영국 의약품규제청, 진통제·항생제 복용 시 햇빛 화상 주의 당부

영국 의약품규제청(MHRA)은 이부프로펜 등 일부 진통제와 항생제, 여드름 치료제가 햇빛으로 인한 피부 화상 위험을 키울 수 있다고 경고했다. 또한 일부 의약품은 더위에 대한 신체 대응 능력에도 영향을 미쳐 탈수 위험을 높일 수 있다고 덧붙였다.

Santé·23/07/2026Résumé IA

المملكة المتحدة توافق على جهاز استنشاق للربو صديق للمناخ

وافقت هيئة تنظيم الأدوية ومنتجات الرعاية الصحية (MHRA) في المملكة المتحدة على جهاز استنشاق جديد للربو "كلينيل مودولايت" يستخدم مادة دافعة أقل تأثيراً في المناخ. الجهاز، الذي سيُطرح في 2026، يقلل البصمة الكربونية بنسبة 90% مع الحفاظ على الفعالية العلاجية.

UK Approves First GLP-1 Receptor Agonist Tablet for Weight Management

The UK's MHRA has approved the first GLP-1 receptor agonist tablet, semaglutide (Wegovy), for weight loss and management. This daily pill offers a more convenient alternative to weekly injections for adults with obesity or those overweight with weight-related conditions.

UK Approves Wegovy Weight-Loss Pill, Expanding Obesity Treatment Options

The UK's MHRA has approved Wegovy, the first GLP-1 receptor agonist tablet for weight loss, making the UK the third country to authorize the pills. This expands treatment options for adults with obesity or overweight with related health conditions.

Guardian UK

3 min de lecture